Faron Pharmaceuticals Limited (AIM:FARN) has had an operationally strong year, according to analysts at Peel Hunt, as the Finnish biotech advances its lead drug candidate, bexmarilimab, through clinical trials.
The antibody therapy, designed to treat myelodysplastic syndrome (MDS), a form of blood cancer, moved from Phase I to Phase II trials, with promising early results.
Regulators have taken note. The US Food and Drug Administration (FDA) has granted bexmarilimab a fast-track designation, a status that speeds up the approval process for drugs targeting serious conditions.
The FDA has also confirmed that a single Phase III trial could be enough to seek marketing approval for both newly diagnosed and relapsed MDS patients.
Early data from the Phase II trial has been encouraging, with 80% of patients responding to the treatment and median survival estimates of around 13.4 months - far better than the five-to-six months typically seen with existing therapies.
With bexmarilimab at a crucial stage, investors are now looking ahead to key milestones. A major update on the ongoing BEXMAB trial in high-risk MDS is expected in April 2025.
Beyond MDS, Faron has broader ambitions for bexmarilimab in solid tumours, with trials such as BLAZE, BEXAR, and MATINS-02 in the pipeline. However, funding remains a key focus. Analysts at Peel Hunt note that securing a partnership deal will be vital to finance these additional studies.
Financially, Faron reported a cash balance of €9.5 million for 2024, up from €6.9 million the previous year, after raising €30.7 million in equity last June.
Operating losses narrowed to €18.7 million from €28.6 million, reflecting lower research and development spending following the completion of the Phase I trial.